Food and Drug Administration Headquarters Consolidation at White Oak, Silver Spring, Maryland

FDA campus

Supplemental EIS for Master Plan Update 2008-2009

The U.S. General Services Administration (GSA) proposes to update the current approved Master Plan for the U.S. Food and Drug Administration (FDA) Headquarters consolidation to accommodate growth from 7,720 to 8,889 employees. Additional building(s) and infrastructure will be needed.

The FDA's growth supports the legislatively mandated expansion of the FDA Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee and Modernization Act (MDUFMA) programs. 

GSA is in the process of developing a Supplemental Environmental Impact Statement (SEIS) that will analyze a range of alternatives, including a no action alternative for the proposed Master Plan update. As part of the SEIS, GSA will study the impacts of each alternative on the human environment.

Public Involvement Opportunities

Scoping for the SEIS was conducted from March 7, 2008 through April 7, 2008.  Comments received during the scoping period were considered during the preparation of the Draft SEIS.

The Draft SEIS is being made available for public comment.  As part of the Draft SEIS, GSA is also inviting comments on historic preservation concerns under Section 106 of the National Historic Preservation Act.  If you have further questions on this project, or would like to obtain a copy of the Draft Supplemental EIS, please contact Ms. Suzanne Hill at (202) 205-5821.  Hard copies of the Draft Supplemental EIS are also available for public review at the following locations:

  • White Oak Public Library, 1170 New Hampshire Avenue, Silver Spring, MD 20904
  • Silver Spring Public Library, 8901 Colesville Road, Silver Spring, MD 20910
  • Beltsville Public Library, 4319 Sellman Road, Beltsville, MD 20705
  • GSA/NCR, 301 7th Street, SW, Room 7600, Washington, DC 20407

A public hearing for the Draft SEIS will be held on April 30, 2009, from 6:30 p.m. to 8:30 p.m., at CHI Center (Multipurpose Room), located at 10501 New Hampshire Avenue, Silver Spring, Maryland.  This hearing is being held to present the findings of the Draft SEIS and to provide the public an opportunity to submit oral and/or written comments on the proposed action.  Anyone with an interest in the project is invited to attend.

Comments may also be submitted by mail during the 45-day review period.  The review period for this Draft SEIS began on March 27, 2009, (date of the Federal Register publication of the notice of availability) and ends May 11, 2009.  Comments must be postmarked by May 11, 2009.  Please send all written comments to:

Suzanne Hill
General Services Administration
NCR/NEPA Lead
301 7th Street, SW
Room 7600
Washington, DC 20407
(202) 708-7671 Fax
suzanne.hill@gsa.gov


Doc ID Name Format Size Publish Date
  Federal Register Notice of Intent PDF 53k 7/1/2008
  Scoping Meeting Brochure PDF 147k 7/1/2008
  Scoping Meeting Presentation PDF 2549k 7/1/2008
  FDA Master Plan Update Volume 1 PDF 7367k 4/17/2009
  FDA Master Plan Update Volume 2 PDF 23665k 4/17/2009
Last Reviewed 4/21/2009